VIA
YMAB

Vident Investment Advisory’s Y-mAbs Therapeutics YMAB Stock Holding History

Vident Investment Advisory’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38,835
Closed -$1.11M – 1245
2021
Q3 		$1.11M Sell
38,835
-2,774
-7% -$87.4K 0.03% 641
2021
Q2 		$1.41M Buy
41,609
+10,170
+32% +$326K 0.04% 548
2021
Q1 		$951K Hold
31,439
– – 0.03% 625
2020
Q4 		$1.56M Buy
31,439
+1,004
+3% +$46.4K 0.06% 388
2020
Q3 		$1.17M Sell
30,435
-2,030
-6% -$80.8K 0.06% 446
2020
Q2 		$1.4M Sell
32,465
-12,177
-27% -$460K 0.07% 354
2020
Q1 		$1.17M Sell
44,642
-3,168
-7% -$92K 0.08% 342
2019
Q4 		$1.49M Sell
47,810
-16,761
-26% -$496K 0.09% 334
2019
Q3 		$1.68M Sell
64,571
-1,845
-3% -$47.1K 0.15% 101
2019
Q2 		$1.52M Sell
66,416
-5,450
-8% -$125K 0.12% 119
2019
Q1 		$1.88M Sell
71,866
-2,355
-3% -$51.7K 0.1% 298
2018
Q4 		$1.51M Buy
+74,221
New +$1.7M 0.08% 319

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vident Investment Advisory's YMAB Position: Q4 2021 in Review

Vident Investment Advisory sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 38,835 shares — an estimated $1.11M sold.

Vident Investment Advisory first reported a position in YMAB in Q4 2018 and held it in 12 quarters. The position peaked at $1.88M in Q1 2019. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Vident Investment Advisory reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 38,835 Y-mAbs Therapeutics shares in Q4 2021, an estimated $1.11M.
  • Vident Investment Advisory first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 12 quarters.
  • Vident Investment Advisory's Y-mAbs Therapeutics position peaked at $1.88M in Q1 2019.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Vident Investment Advisory's 13F filing for Q4 2021, filed 14 Feb 2022.